Piramal Pharma Limited CC-Jan26.pdf · 2026-01-29
I have two questions. My first question relates to the 2030 projections. Do we stand, or would you like to revise it?
The second question relates to taxation. We see that there is continued negative profit over the quarters, and yet the tax incidence continues. Now, we have been explained that this is because of the divergent profitability of the various plants. Now, this argument, of course, is valid, but in the long run, how do you propose to mitigate this argument by ensuring profitability of the loss making plants or closure or reduction of those plants?